- Home
- CHRS vs SKYE Comparison
CHRS vs SKYE Comparison
Compare CHRS & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SKYE
- Stock Information
- Founded
- CHRS 2010
- SKYE 2012
- Country
- CHRS United States
- SKYE United States
- Employees
- CHRS N/A
- SKYE N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- SKYE Health Care
- Exchange
- CHRS Nasdaq
- SKYE Nasdaq
- Market Cap
- CHRS 100.9M
- SKYE 108.3M
- IPO Year
- CHRS 2014
- SKYE N/A
- Fundamental
- Price
- CHRS $1.10
- SKYE $4.28
- Analyst Decision
- CHRS Strong Buy
- SKYE Buy
- Analyst Count
- CHRS 4
- SKYE 6
- Target Price
- CHRS $6.13
- SKYE $18.67
- AVG Volume (30 Days)
- CHRS 3.1M
- SKYE 178.7K
- Earning Date
- CHRS 11-06-2024
- SKYE 11-07-2024
- Dividend Yield
- CHRS N/A
- SKYE N/A
- EPS Growth
- CHRS N/A
- SKYE N/A
- EPS
- CHRS N/A
- SKYE N/A
- Revenue
- CHRS $304,340,000.00
- SKYE N/A
- Revenue This Year
- CHRS $3.33
- SKYE N/A
- Revenue Next Year
- CHRS $16.77
- SKYE N/A
- P/E Ratio
- CHRS N/A
- SKYE N/A
- Revenue Growth
- CHRS 44.19
- SKYE N/A
- 52 Week Low
- CHRS $0.66
- SKYE $1.44
- 52 Week High
- CHRS $3.70
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- CHRS 69.14
- SKYE 37.36
- Support Level
- CHRS $0.70
- SKYE $4.32
- Resistance Level
- CHRS $0.89
- SKYE $5.67
- Average True Range (ATR)
- CHRS 0.10
- SKYE 0.53
- MACD
- CHRS 0.04
- SKYE -0.15
- Stochastic Oscillator
- CHRS 93.70
- SKYE 2.83
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.